Intermittent Fasting: Does It Really Work for Weight Loss?

Intermittent Fasting: Does It Really Work for Weight Loss?

A recent study raised questions about the effectiveness of intermittent fasting for weight loss, suggesting that calorie restriction might be more effective. However, experts emphasize the importance of food quality and highlight the numerous health benefits of intermittent fasting beyond weight loss, including improved gut health and insulin sensitivity.

Jazz Pharmaceuticals’ Epidiolex Trial in Japan Shows Mixed Results for Rare Epilepsy Treatment

Jazz Pharmaceuticals’ Epidiolex Trial in Japan Shows Mixed Results for Rare Epilepsy Treatment

Jazz Pharmaceuticals’ Epidiolex, a cannabidiol oral solution for treating rare forms of epilepsy, showed mixed results in a Phase 3 trial in Japan. While the trial did not achieve its primary goal of reducing seizure frequency, there were improvements in other areas, and no new safety concerns were identified. The company plans to continue collecting data and engage with Japanese regulatory authorities regarding a potential new drug application.

WHO Allows Early Mpox Vaccine Purchases to Speed Up Africa Response

WHO Allows Early Mpox Vaccine Purchases to Speed Up Africa Response

The World Health Organization (WHO) has eased its rules, allowing organizations like Gavi and UNICEF to purchase mpox vaccines before WHO approval, aiming to expedite vaccine distribution to Africa amidst a growing outbreak. This decision comes as the WHO is expected to grant emergency use authorization to two vaccines in September. The move addresses concerns about potential delays in vaccine access for low-income countries.

Targeted Therapeutics Market to Reach US$ 118.6 Billion by 2034

Targeted Therapeutics Market to Reach US$ 118.6 Billion by 2034

The global targeted therapeutics market is experiencing significant growth, driven by increasing cancer cases and a surge in product approvals. This market is expected to reach US$ 118.6 Billion by 2034, driven by a 6.4% CAGR. The report highlights the rise of precision medicine and the potential of targeted therapies in treating autoimmune and inflammatory diseases.

UK Approves Alzheimer’s Drug Leqembi Despite Cost Concerns

UK Approves Alzheimer’s Drug Leqembi Despite Cost Concerns

The UK’s Medicines and Healthcare products Regulatory Agency has approved Leqembi, an Alzheimer’s drug developed by Eisai and Biogen, for treating early-stage Alzheimer’s disease. However, the National Institute for Health and Care Excellence (NICE) has declined to recommend the drug for use on the NHS due to its high cost and limited benefits.

Prebiotics: The Unsung Heroes of Gut Health

Prebiotics: The Unsung Heroes of Gut Health

Prebiotics are non-digestible fibers that act as food for beneficial gut bacteria, supporting a healthy gut microbiome and contributing to overall health. Learn about the benefits of prebiotics, how they differ from probiotics, and which foods are rich in these essential nutrients.

Scroll to Top